Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma

Jurczak, Wojciech; Ramanathan, Sundra; Giri, Pratyush; Romano, Alessandra; Móciková, Heidi; Clancy, Jill S.; Lechuga, Mariajosé; Casey, Michelle; Giza, Agnieszka; Heß, Georg

doi:10.1080/10428194.2017.1357175

Cited by 8 publications

(5 citation statements)

References 19 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The improved safety profile of acalabrutinib versus the other targeted monotherapies, and within the Note: The baseline characteristics for acalabrutinib were derived by using individual patient-level data from the ACE-LY-004 trial. 22,23 The baseline characteristics for temsirolimus were extracted from 3 temsirolimus trials (MCL3001/RAY, OPTIMAL, and Jurczak et al 35 ). 35e37 One patient with an ECOG performance status of 3 in the ACE-LY-004 trial was excluded from the analysis.…”

Section: Discussionmentioning

confidence: 99%

Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma

Telford¹,

Kabadi²,

Abhyankar³

et al. 2019

Clinical Therapeutics

View full text Add to dashboard Cite

Purpose: Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma that can be either aggressive or indolent. Although MCL usually responds well to initial treatment with chemotherapybased regimens, the disease often relapses or becomes refractory within a few years. Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor with minimal off-target activity. WIthout head-to-head clinical trial data, estimation of the comparative efficacy and safety of new therapeutic entities provides valuable information for patients, clinicians, and health care payers. The objective of this analysis was to compare the efficacy and safety of acalabrutinib versus other targeted therapies employed for the treatment of relapsed/refractory MCL by using matching-adjusted indirect comparisons. Methods: Individual data from 124 patients treated with acalabrutinib in the Phase II ACE-LY-004 trial were adjusted to match average baseline characteristics of populations from studies using alternative targeted treatment regimens for relapsed/refractory MCL (for monotherapy: ibrutinib, bortezomib, lenalidomide, and temsirolimus; for combination therapies: ibrutinib + rituximab, bendamustine + rituximab, and lenalidomide + rituximab). Patient populations were matched on age, sex, race, Eastern Cooperative Oncology Group performance status, Simplified MCL International Prognostic Index score, tumor bulk, lactate dehydrogenase concentration, extranodal disease, bone marrow involvement, and number of previous treatment regimens. Outcomes assessed

show abstract

Section: Discussionmentioning

confidence: 99%

Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma

Telford¹,

Kabadi²,

Abhyankar³

et al. 2019

Clinical Therapeutics

View full text Add to dashboard Cite

show abstract

“…The significance of the 3 weekly 175 mg doses remains, however, obscure. Thus, Jurczak et al conducted a phase IV randomized trial comparing the approved 175/75 mg weekly dose schedule with a fixed 75 mg weekly dose from the beginning [ 61 ]. Temsirolimus was again given until PD or unacceptable toxicity.…”

Section: Clinical Applications Of M-tor Inhibitors In B Cell Lymphomasmentioning

confidence: 99%

The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects

Karatrasoglou,

Dimou,

Piperidou

et al. 2023

IJMS

View full text Add to dashboard Cite

Non-Hodgkin lymphoma’s (NHL) incidence is rising over time, and B cell lymphomas comprise the majority of lymphomas. The phosphoinositide 3-kinase (PI3K)/v-akt murine thymoma viral oncogene homologue 1 (Akt)/mammalian target of the rapamycin (mTOR) signaling pathway plays a critical role in a variety of cellular processes, such as cell proliferation and survival. Its role in lymphomagenesis is confirmed in many different types of B cell lymphomas. This review is mainly focused on the PI3K/v-akt/mTOR pathway-related oncogenic mechanisms in B cell NHLs with an emphasis on common B cell lymphoma types [diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)]. Furthermore, it summarizes the literature regarding the clinical applications of the mTOR inhibitors temsirolimus and everolimus in B cell NHLs, which have been tested in a range of clinical trials enrolling patients with B cell malignancies, either as monotherapy or in combination with other agents or regimens.

show abstract

“… 66 ). Temsirolimus was the first mTOR inhibitor class drug to be shown to improve survival in patients with advanced renal cell carcinoma (Refs 67 , 68 ). Increased PI3K/AKT expression and activation are common in renal cell cancer and this drug is used in the first-line treatment of metastatic renal cell cancer with poor prognosis (Ref.…”

Section: Autophagy and Age-related Diseasesmentioning

confidence: 99%

Autophagic mechanisms in longevity intervention: role of natural active compounds

Akça

Ayan

Çetinkaya

et al. 2023

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

The term ‘autophagy’ literally translates to ‘self-eating’ and alterations to autophagy have been identified as one of the several molecular changes that occur with aging in a variety of species. Autophagy and aging, have a complicated and multifaceted relationship that has recently come to light thanks to breakthroughs in our understanding of the various substrates of autophagy on tissue homoeostasis. Several studies have been conducted to reveal the relationship between autophagy and age-related diseases. The present review looks at a few new aspects of autophagy and speculates on how they might be connected to both aging and the onset and progression of disease. Additionally, we go over the most recent preclinical data supporting the use of autophagy modulators as age-related illnesses including cancer, cardiovascular and neurodegenerative diseases, and metabolic dysfunction. It is crucial to discover important targets in the autophagy pathway in order to create innovative therapies that effectively target autophagy. Natural products have pharmacological properties that can be therapeutically advantageous for the treatment of several diseases and they also serve as valuable sources of inspiration for the development of possible new small-molecule drugs. Indeed, recent scientific studies have shown that several natural products including alkaloids, terpenoids, steroids, and phenolics, have the ability to alter a number of important autophagic signalling pathways and exert therapeutic effects, thus, a wide range of potential targets in various stages of autophagy have been discovered. In this review, we summarised the naturally occurring active compounds that may control the autophagic signalling pathways.

show abstract

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma

Cited by 8 publications

References 19 publications

Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma

Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma

The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects

Autophagic mechanisms in longevity intervention: role of natural active compounds

Contact Info

Product

Resources

About